The Effect of Metastatic Site and Decade of Diagnosis on the Individual Burden of Metastatic Melanoma: Contemporary Estimates of Average Years of Life Lost

REFERENCES

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999;40:35–42.
   PubMed Web of Science ®Google Scholar
• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893–1907.
   PubMed Web of Science ®Google Scholar
• Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Critical Reviews in Oncology/Hematology 2010;74:27–39.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology and End Results (SEER) Program. National Cancer Institute 2003–2007. http://seer.cancer.gov/statfacts/html/melan.html, accessed February 3, 2011.
   Google Scholar
• http://fundedresearch.cancer.gov/, accessed August 9, 2012.
   Google Scholar
• Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 2005;92:241–245.
   PubMed Web of Science ®Google Scholar
• Ekwueme DU, Guy GP, Jr., Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol 2011;65:S133–S143.
   PubMed Web of Science ®Google Scholar
• Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 2011;29:863–874.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008;100:1755–1762.
   PubMed Web of Science ®Google Scholar
• Horm JW, Sondik EJ. Person-years of life lost due to cancer in the United States, 1970 and 1984. Am J Public Health 1989;79:1490–1493.
   PubMed Web of Science ®Google Scholar
• Taylor D, Nyambose JKK, D. Earle CC, Thompson D. Impact of mortality due to malignant melanoma versus other cancers. J Clin Oncol 2008;26: (May 20 suppl; abstr 20016) 2008.
   Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199–6206.
   PubMed Web of Science ®Google Scholar
• Rhodes AR. Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer? Cancer 1995;75:613–636.
   PubMed Web of Science ®Google Scholar
• Wagner JD, Bergman D. Primary cutaneous melanoma: surgical management and other treatment options. Curr Treat Options Oncol 2003;4:177–185.
   PubMedGoogle Scholar
• Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(Suppl 1):S11–S14.
   PubMedGoogle Scholar
• Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K; Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33:484–496.
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4: 748–759.
   PubMed Web of Science ®Google Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21–34.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011;364(26):2507–2516.
   Web of Science ®Google Scholar
• Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008;5:557–561.
   PubMedGoogle Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809–819.
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010;21(Suppl 7): vii339–vii344.
   PubMedGoogle Scholar